MINZOYA
Clinical safety rating
cautionComprehensive clinical and safety monograph for MINZOYA (MINZOYA).
Zinc pyrithione is an antimicrobial agent that inhibits fungal growth by disrupting membrane transport and inhibiting mitochondrial function, leading to cell death.
| Metabolism | Not extensively metabolized; minimal systemic absorption after topical application. |
| Excretion | Primarily hepatic metabolism with renal excretion of metabolites (50-60% as unchanged drug and conjugates); approximately 30-40% fecal elimination. |
| Half-life | Terminal elimination half-life of 20-30 hours; at steady state after 5-7 days, half-life reflects accumulation for once-daily dosing. |
| Protein binding | Approximately 95% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5-0.8 L/kg, consistent with distribution into total body water and some tissue binding. |
| Bioavailability | Oral bioavailability of 70-80% due to first-pass metabolism; food does not significantly affect absorption. |
| Onset of Action | Oral: 1-2 hours for measurable serum concentrations; clinical effect (reduction in seizure frequency) observed within 2 weeks. |
| Duration of Action | 24 hours with once-daily dosing due to sustained concentrations; steady state achieved in 5-7 days. |
| Molecular Weight | 387.47 |
Intravenous infusion of 300 mg over 30 minutes every 4 weeks.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. No recommended dose. |
| Geriatric use | No specific dose adjustment recommended based on age. Clinical studies included limited number of patients aged ≥65 years; no overall differences in safety or efficacy observed. |
| 1st trimester | Avoid use due to increased risk of congenital malformations, particularly neural tube defects and cardiovascular anomalies. Animal studies show teratogenicity at clinically relevant doses. |
| 2nd trimester | Avoid use. Risk of fetal toxicity, including potential for antiandrogenic effects on male fetal development based on animal data. |
| 3rd trimester | Avoid use. Potential for neonatal withdrawal syndrome and respiratory depression if used near term. |
Clinical note
Comprehensive clinical and safety monograph for MINZOYA (MINZOYA).
| Placental transfer | Extensive placental transfer occurs; the drug crosses the placenta readily, achieving fetal plasma concentrations similar to maternal levels. |
| Breastfeeding | Minzoya is excreted into human breast milk. Due to the potential for serious adverse reactions in nursing infants, including sedation and respiratory depression, breastfeeding is not recommended during treatment and for at least 7 days after the last dose. |
| Lactation Rating | L5 (Avoid) |
| Teratogenic Risk | Minzoya (misoprostol) is contraindicated in pregnancy due to proven teratogenicity. First trimester exposure is associated with Moebius syndrome, limb defects, and fetal death. Second and third trimester use is limited to induction of labor; risk of uterine hyperstimulation and fetal distress. Overall, pregnancy category X. |
| Fetal Monitoring | In third trimester use for labor induction: continuous fetal heart rate monitoring and uterine activity monitoring due to risk of hyperstimulation, uterine rupture, and nonreassuring fetal status. For postpartum hemorrhage: monitor uterine tone, blood loss, vital signs and fetal heart rate if fetus still in utero. |
| Fertility Effects | No direct effects on fertility reported in humans. In animal studies, no significant impact on fertility. Misoprostol is used off-label for cervical ripening prior to intrauterine procedures, but no evidence of long-term fertility impairment. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to Minzoya or any component of the formulationConcurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) due to risk of QTc prolongationHistory of torsades de pointes or congenital long QT syndromeSevere hepatic impairment (Child-Pugh class C)
| Precautions | For external use only. Avoid contact with eyes. If irritation occurs, discontinue use. May cause local skin reactions such as itching, burning, or erythema. |
| Food/Dietary | Minzoya has no specific food interactions; however, caution with high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) is generally not required as Minzoya does not inhibit MAO-A. Grapefruit and grapefruit juice may increase mirtazapine levels; consider avoiding excessive consumption. Alcohol should be avoided due to additive sedation. Caffeine may counteract sedative effects. |
| Clinical Pearls | Minzoya (mirtazapine) is a noradrenergic and specific serotonergic antidepressant (NaSSA). It is particularly useful for patients with insomnia and poor appetite due to its sedative and appetite-stimulating effects. Monitor for weight gain, especially with long-term use. Avoid concomitant use with MAOIs; allow a 14-day washout. Dosing at bedtime minimizes daytime sedation. Anticholinergic effects are minimal; however, caution in patients with hepatic impairment (dose reduction recommended) and elderly patients due to increased risk of falls from orthostatic hypotension. Rare but serious adverse effects include agranulocytosis (monitor for infection). Onset of therapeutic effect is typically 2-4 weeks. |
| Patient Advice | Take Minzoya exactly as prescribed, usually once daily at bedtime due to its sedative effect. · Do not stop taking this medication abruptly without consulting your doctor, as withdrawal symptoms may occur. · Avoid alcohol and other central nervous system depressants while taking Minzoya, as they can increase sedation. · Report any signs of infection such as fever, sore throat, or mouth sores immediately, as this may indicate a low white blood cell count. · Weight gain and increased appetite are common; monitor your weight and discuss dietary adjustments with your healthcare provider. · May cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how this medication affects you. · If you miss a dose, skip the missed dose and take the next dose at the regular time. Do not double the dose. · Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. · This medication may take several weeks to reach full effect; do not stop taking it without consulting your doctor. · Keep out of reach of children and store at room temperature away from moisture and heat. |
Loading safety data…